Matches in SemOpenAlex for { <https://semopenalex.org/work/W2243836849> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2243836849 endingPage "6601" @default.
- W2243836849 startingPage "6601" @default.
- W2243836849 abstract "6601 Background: SGN-30 is a chimeric monoclonal antibody (mAb) directed against the CD30 antigen expressed on hematologic malignancies. SGN-30 was well tolerated in phase I and objective responses were seen. Methods: Refractory or recurrent CD30 positive ALCL patients, ECOG performance status 0–2, are treated in a multicenter, single arm phase II study. SGN-30 at 6 mg/kg is administered by short IV infusion weekly for 6 consecutive doses. A two stage statistical design provides a 90% power to detect an objective tumor response rate of at least 30%. Results: Patient Characteristics: 8 patients (3 male, 5 female) with median age 59 years have been enrolled. Median number of prior therapies is 2.5 (range 1–5). 88% of patients have received prior CHOP. Efficacy: 6 patients are evaluable for efficacy with 1 CR, 1 PR, 1 SD and 3 PD. The patient with a CR had a chest wall mass measuring 5.1 x 2.0 cm which disappeared completely after 6 doses of SGN-30. The duration of the CR is 49+ days. The patient with a PR had extensive cutaneous and nodal disease and constitutional symptoms. After treatment there was resolution of all skin lesions, reduction in lymphadenopathy and improvement in the constitutional symptoms. Assessment of duration of response was not possible as the protocol (subsequently amended) did not permit further therapy and the patient was switched to chemotherapy after 28 days. Tolerability: The most common adverse events included cough, diarrhea, fatigue, hoarseness, muscle weakness, rigors and vomiting. Each occurred in at least 2 patients. Only one grade 3/4 adverse event of catheter related infection was thought possibly related to SGN-30. Conclusions: The drug is well tolerated and shows signs of antitumor activity. Recruitment into the study continues. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Seattle Genetics Seattle Genetics" @default.
- W2243836849 created "2016-06-24" @default.
- W2243836849 creator A5015364745 @default.
- W2243836849 creator A5026378974 @default.
- W2243836849 creator A5029363412 @default.
- W2243836849 creator A5037882455 @default.
- W2243836849 creator A5046549002 @default.
- W2243836849 creator A5078397650 @default.
- W2243836849 creator A5080887633 @default.
- W2243836849 creator A5082606841 @default.
- W2243836849 date "2005-06-01" @default.
- W2243836849 modified "2023-10-07" @default.
- W2243836849 title "Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)" @default.
- W2243836849 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.6601" @default.
- W2243836849 hasPublicationYear "2005" @default.
- W2243836849 type Work @default.
- W2243836849 sameAs 2243836849 @default.
- W2243836849 citedByCount "16" @default.
- W2243836849 countsByYear W22438368492014 @default.
- W2243836849 crossrefType "journal-article" @default.
- W2243836849 hasAuthorship W2243836849A5015364745 @default.
- W2243836849 hasAuthorship W2243836849A5026378974 @default.
- W2243836849 hasAuthorship W2243836849A5029363412 @default.
- W2243836849 hasAuthorship W2243836849A5037882455 @default.
- W2243836849 hasAuthorship W2243836849A5046549002 @default.
- W2243836849 hasAuthorship W2243836849A5078397650 @default.
- W2243836849 hasAuthorship W2243836849A5080887633 @default.
- W2243836849 hasAuthorship W2243836849A5082606841 @default.
- W2243836849 hasConcept C121332964 @default.
- W2243836849 hasConcept C126322002 @default.
- W2243836849 hasConcept C141071460 @default.
- W2243836849 hasConcept C142424586 @default.
- W2243836849 hasConcept C197934379 @default.
- W2243836849 hasConcept C2776694085 @default.
- W2243836849 hasConcept C2777872185 @default.
- W2243836849 hasConcept C2778375690 @default.
- W2243836849 hasConcept C2779338263 @default.
- W2243836849 hasConcept C31760486 @default.
- W2243836849 hasConcept C71924100 @default.
- W2243836849 hasConcept C87355193 @default.
- W2243836849 hasConcept C90924648 @default.
- W2243836849 hasConceptScore W2243836849C121332964 @default.
- W2243836849 hasConceptScore W2243836849C126322002 @default.
- W2243836849 hasConceptScore W2243836849C141071460 @default.
- W2243836849 hasConceptScore W2243836849C142424586 @default.
- W2243836849 hasConceptScore W2243836849C197934379 @default.
- W2243836849 hasConceptScore W2243836849C2776694085 @default.
- W2243836849 hasConceptScore W2243836849C2777872185 @default.
- W2243836849 hasConceptScore W2243836849C2778375690 @default.
- W2243836849 hasConceptScore W2243836849C2779338263 @default.
- W2243836849 hasConceptScore W2243836849C31760486 @default.
- W2243836849 hasConceptScore W2243836849C71924100 @default.
- W2243836849 hasConceptScore W2243836849C87355193 @default.
- W2243836849 hasConceptScore W2243836849C90924648 @default.
- W2243836849 hasIssue "16_suppl" @default.
- W2243836849 hasLocation W22438368491 @default.
- W2243836849 hasOpenAccess W2243836849 @default.
- W2243836849 hasPrimaryLocation W22438368491 @default.
- W2243836849 hasRelatedWork W1967853306 @default.
- W2243836849 hasRelatedWork W2045177263 @default.
- W2243836849 hasRelatedWork W2109512293 @default.
- W2243836849 hasRelatedWork W2351476339 @default.
- W2243836849 hasRelatedWork W2378369323 @default.
- W2243836849 hasRelatedWork W2464877492 @default.
- W2243836849 hasRelatedWork W2528057197 @default.
- W2243836849 hasRelatedWork W2793494425 @default.
- W2243836849 hasRelatedWork W3191690061 @default.
- W2243836849 hasRelatedWork W4318426573 @default.
- W2243836849 hasVolume "23" @default.
- W2243836849 isParatext "false" @default.
- W2243836849 isRetracted "false" @default.
- W2243836849 magId "2243836849" @default.
- W2243836849 workType "article" @default.